CD33 specific chimeric antigen receptors for cancer immunotherapy
US9944702B2 · kind B2 · utility
21Cited by
0References
29Claims
0Family size
Assignee
Inventor
Key dates
| Filing date | Apr 2, 2015 |
| Grant date | Apr 17, 2018 |
| Priority date | — |
| Expiry date | Apr 2, 2035 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC07K2319/03
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The present invention relates to Chimeric Antigen Receptors (CAR) that are recombinant chimeric proteins able to redirect immune cell specificity and reactivity toward selected membrane antigens, and more particularly in which extracellular ligand binding is a scFV derived from a CD33 monoclonal antibody, conferring specific immunity against CD33 positive cells. The engineered immune cells endowed with such CARs are particularly suited for treating lymphomas and leukemia.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.